Spinal Cord Injury News and Research

RSS

A spinal cord injury usually begins with a sudden, traumatic blow to the spine that fractures or dislocates vertebrae. The damage begins at the moment of injury when displaced bone fragments, disc material, or ligaments bruise or tear into spinal cord tissue. Most injuries to the spinal cord don't completely sever it. Instead, an injury is more likely to cause fractures and compression of the vertebrae, which then crush and destroy the axons, extensions of nerve cells that carry signals up and down the spinal cord between the brain and the rest of the body. An injury to the spinal cord can damage a few, many, or almost all of these axons. Some injuries will allow almost complete recovery. Others will result in complete paralysis.

Acorda Therapeutics reports AMPYRA gross sales of $3.4 million for first-quarter 2010

Acorda Therapeutics, Inc. today announced its financial results for the first quarter of 2010.

30 Apr 2010

UC Irvine scientists receive CIRM grants for stem cell research

Two UC Irvine scientists will receive grants totaling more than $2.6 million to study the underlying biology of stem cells aimed at treating spinal cord injury, cancer and other disorders.

30 Apr 2010

BioTime to acquire Singapore-based company, ES Cell International

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced that it has agreed to acquire the Singapore-based company ES Cell International Pte Ltd.

30 Apr 2010

InVivo Therapeutics CEO to be honored as one of Irish Life Science 50

InVivo Therapeutics Corporation CEO Frank Reynolds will be honored by the Irish Voice and Irish America Magazine, in collaboration with the Irish Government, as one of the 'Irish Life Science 50.' The award is the first honor to be given to influential Irish Americans for their work in the field of life sciences and is aimed to recognize "diverse accomplishments and advancements in the industry," according the Irish Voice.

23 Apr 2010

Hospital for Special Care launches ALS Clinical Trials Unit at Neuromuscular Center

Hospital for Special Care announced today the launch of the region's first Amyotrophic Lateral Sclerosis (ALS) Clinical Trials Unit at its Neuromuscular Center. The new unit will be headed by Jinsy A. Andrews, M.D., a physician researcher recruited from Columbia University. Dr. Andrews, Director of Research & Clinical Trials Unit, Hospital for Special Care, specializes in neuromuscular research and will facilitate the hospital's first clinical trial for ALS upon her arrival.

23 Apr 2010

StemCells to initiate second clinical trial of HuCNS-SC human neural stem cells in NCL

StemCells, Inc. announced today that it has submitted a protocol to the FDA for initiation of a second clinical trial of its proprietary HuCNS-SC human neural stem cells in neuronal ceroid lipofuscinosis, which is also often referred to as Batten disease.

22 Apr 2010

Acorda Therapeutics to initiate Phase 1 clinical trial of GGF2 for heart failure in mid-2010

Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.

20 Apr 2010

OECs may hold promise for pediatric cerebral palsy treatment

A unique cell type that supports and surrounds (ensheathes) neurons within the nose (olfactory system) known as olfactory ensheathing cells (OECs), possess the ability to regenerate, are relatively easy to obtain, and have become prime candidates for transplantation to repair a number of lesions in the central nervous system (CNS).

19 Apr 2010

Exposure to dust after WTC collapse impairs ability to detect odors and sense irritants

Individuals involved in rescue, recovery, demolition, and clean-up after the World Trade Center (WTC) disaster on September 11, 2001, were exposed to a complex mixture of airborne smoke, dust, combustion gases, acid mists, and metal fumes. The impact of this exposure on responders' upper and lower respiratory function has been well documented, but little is known about its impact on their sensitivity to odor and irritants.

19 Apr 2010

Courage Center accepts nominations for three employment-related annual awards

Minneapolis-based Courage Center, a nonprofit rehabilitation and resource center, is accepting nominations for three employment-related annual awards: the Jay and Rose Phillips Award, the Phillips Caregiver Award and the Judd Jacobson Memorial Award.

17 Apr 2010

Positive results from NovaBay Pharmaceuticals' Phase 2a trial of NVC-422

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.

15 Apr 2010

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.

13 Apr 2010

XenoPort to present arbaclofen placarbil, XP13512 trial data at 62nd American Academy of Neurology meeting

XenoPort announced today that new data from clinical trials of its product candidates arbaclofen placarbil and XP13512 (gabapentin enacarbil) will be presented at the 62nd Annual American Academy of Neurology meeting in Toronto, Ontario.

12 Apr 2010

Sitting down during hospital room visits induces perception of having stayed longer

Sitting down on the job has its advantages. New data from The University of Kansas Hospital finds that patients perceive doctors who sit down during their hospital room visits stay longer than doctors who stand during the visit – even when doctors who sit don't stay as long as doctors who stand.

7 Apr 2010

KMI receives 2-year Phase II SBIR grant to study new treatment for TBI

Kinetic Muscles Inc., a leading innovator of neurorehabilitation technology, announced it has received a 2-year Phase II SBIR grant to study a new treatment for veterans returning from active duty with traumatic brain injury.

5 Apr 2010

Beike Biotechnology awarded ISO9001 certification for implementation of comprehensive QMS

Beike Biotechnology Co. Ltd., one of the world's leading biotechnology companies focusing on adult stem cell therapies, has been awarded ISO9001 certification by the International Organization for Standardization ("ISO"). This internationally recognized designation signifies Beike has established a Quality Management System (QMS) that complies with ISO9001 standards.

3 Apr 2010

Multidisciplinary approach holds promise for treating patients with spinal cord injuries

Although new developments in the management of spinal cord injuries are on the horizon, any eventual cure for the condition is more likely to involve a multidisciplinary approach, drawing from expertise in several fields, according to a review article published in the April 2010 issue of the Journal of the American Academy of Orthopaedic Surgeons.

2 Apr 2010

Recipients of Pfizer Canada's third Neuropathic Pain Research Awards Competition announced

Pfizer Canada is pleased to announce the recipients of its third Neuropathic Pain Research Awards Competition, which aims to fund and support Canadian innovation within independent neuropathic pain research in the areas of basic biomedical, clinical and health sciences.

31 Mar 2010

Medtronic announces enrollment of first European patients in randomized controlled trial of ITB Therapy

Medtronic, Inc. today announced the enrollment of the first European patients in the largest randomized controlled trial to date to investigate the benefits of ITB Therapy(R) (Intrathecal Baclofen) in post-stroke patients affected by spasticity. The announcement comes as the World Congress for Neurorehabilitation is taking place in Vienna, Austria.

26 Mar 2010

Study identifies cytokine signaling pathway that induces breakdown of disused skeletal muscle

A new study in the Journal of Cell Biology identifies a cytokine signaling pathway that induces the breakdown of disused skeletal muscle. Blocking this pathway could prevent immobilized patients from losing their muscle tissue.

23 Mar 2010

Spinal Cord Injury News and Research

Further Reading

Acorda Therapeutics reports AMPYRA gross sales of $3.4 million for first-quarter 2010

UC Irvine scientists receive CIRM grants for stem cell research

BioTime to acquire Singapore-based company, ES Cell International

InVivo Therapeutics CEO to be honored as one of Irish Life Science 50

Hospital for Special Care launches ALS Clinical Trials Unit at Neuromuscular Center

StemCells to initiate second clinical trial of HuCNS-SC human neural stem cells in NCL

Acorda Therapeutics to initiate Phase 1 clinical trial of GGF2 for heart failure in mid-2010

OECs may hold promise for pediatric cerebral palsy treatment

Exposure to dust after WTC collapse impairs ability to detect odors and sense irritants

Courage Center accepts nominations for three employment-related annual awards

Positive results from NovaBay Pharmaceuticals' Phase 2a trial of NVC-422

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

XenoPort to present arbaclofen placarbil, XP13512 trial data at 62nd American Academy of Neurology meeting

Sitting down during hospital room visits induces perception of having stayed longer

KMI receives 2-year Phase II SBIR grant to study new treatment for TBI

Beike Biotechnology awarded ISO9001 certification for implementation of comprehensive QMS

Multidisciplinary approach holds promise for treating patients with spinal cord injuries

Recipients of Pfizer Canada's third Neuropathic Pain Research Awards Competition announced

Medtronic announces enrollment of first European patients in randomized controlled trial of ITB Therapy

Study identifies cytokine signaling pathway that induces breakdown of disused skeletal muscle

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News